NASDAQ:BDSIBioDelivery Sciences International Stock Price, Forecast & News

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BDSI stock has increased by 21.5% and is now trading at $4.81. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioDelivery Sciences International.

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for BioDelivery Sciences International.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. The specialty pharmaceutical company had revenue of $38.28 million for the quarter, compared to analyst estimates of $33.19 million. BioDelivery Sciences International had a positive return on equity of 23.61% and a negative net margin of 5.01%. View BioDelivery Sciences International's earnings history.

8 brokerages have issued 1-year price objectives for BioDelivery Sciences International's stock. Their forecasts range from $8.00 to $9.25. On average, they anticipate BioDelivery Sciences International's share price to reach $8.71 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price. View analysts' price targets for BioDelivery Sciences International.

Media coverage about BDSI stock has trended positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutBioDelivery Sciences International.

Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Baidu (BIDU), JD.Com (JD), Crispr Therapeutics (CRSP) and Gilead Sciences (GILD).

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.43%), Systematic Financial Management LP (2.39%), Emerald Advisers LLC (2.18%), State Street Corp (1.92%), Emerald Mutual Fund Advisers Trust (1.98%) and Nuveen Asset Management LLC (1.71%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith. View institutional ownership trends for BioDelivery Sciences International.

BDSI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deutsche Bank AG, Two Sigma Investments LP, Assenagon Asset Management S.A., BlackRock Inc., Bank of New York Mellon Corp, WINTON GROUP Ltd, and Squarepoint Ops LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, and Thomas B Smith. View insider buying and selling activity for BioDelivery Sciences International.

BDSI stock was bought by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., Stonepine Capital Management LLC, AQR Capital Management LLC, Systematic Financial Management LP, Grandeur Peak Global Advisors LLC, DG Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., and Cadence Capital Management LLC. View insider buying and selling activity for BioDelivery Sciences International.

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BDSI stock can currently be purchased for approximately $4.81.

BioDelivery Sciences International has a market capitalization of $480.52 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 178 workers across the globe.

The official website for BioDelivery Sciences International is www.bdsi.com.

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]